Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) (NCT06596694)
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
🩺 Plain-English Summary (8th-Grade Level)
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Who can join: Review the eligibility criteria below.
Location: UCLA Hematology Oncology Santa Monica ( Site 1205) — Santa Monica, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (62 Sites)
Showing the first 25 of 62 sites.
- UCLA Hematology Oncology Santa Monica ( Site 1205) — Santa Monica, California
- University of Colorado Cancer Center ( Site 1200) — Aurora, Colorado
- Sibley Memorial Hospital ( Site 1208) — Washington D.C., District of Columbia
- University of Florida ( Site 1202) — Gainesville, Florida
- Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213) — Miami Beach, Florida
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203) — Marietta, Georgia
- University of Chicago Medical Center ( Site 1204) — Chicago, Illinois
- Renown Regional Medical Center ( Site 1221) — Reno, Nevada
- NYU Langone Hospital - Long Island ( Site 1230) — Mineola, New York
- Perlmutter NYU Cancer Center ( Site 1212) — New York, New York
- Scott & White Medical Center-Temple ( Site 1224) — Temple, Texas
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 1207) — Roanoke, Virginia
- University of Wisconsin ( Site 1210) — Madison, Wisconsin
- Westmead Hospital ( Site 0100) — Sydney, New South Wales
- Alfred Health ( Site 0102) — Melbourne, Victoria
- Austin Health ( Site 0103) — Melbourne, Victoria
- One Clinical Research ( Site 0104) — Mount Pleasant, Western Australia
- QEII Health Sciences Centre - Victoria General Site ( Site 0200) — Halifax, Nova Scotia
- Sunnybrook Research Institute - Odette Cancer Centre ( Site 0206) — Toronto, Ontario
- McGill University Health Centre ( Site 0202) — Montreal, Quebec
- Fundacion Arturo Lopez Perez ( Site 0301) — Santiago, Region M. de Santiago
- Centro de Oncología de Precisión ( Site 0305) — Santiago, Region M. de Santiago
- Clínica UC San Carlos de Apoquindo ( Site 0302) — Santiago, Region M. de Santiago
- Bradfordhill ( Site 0300) — Santiago, Region M. de Santiago
- The First Affiliated Hospital of Anhui Medical University ( Site 0405) — Hefei, Anhui
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Cancer
- Advancing Nursing Practices in Hospital Oncology Care — New York, New York
- Avatrombopag vs. Placebo for CIT in GI Malignancies — Miami, Florida
- A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) — New Haven, Connecticut
- Dyadic Sleep Study — Coral Gables, Florida
- EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. — Cleveland, Ohio
- Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) — Los Angeles, California
Explore by condition: All Gastrointestinal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.